Emergent Biosolutions (NYSE:EBS) : $3.5 million worth of transactions were on upticks in Emergent Biosolutions (NYSE:EBS), compared to $3.2 million on downticks. The ratio between the two was 1.09, whereas, the net money flow stood at a healthy $0.3 million on Wednesdays session. The consistent buying on upticks in the stock accounted for $0.01million worth of trades. The total money flow into the stock stood at $0.01 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.67%. The stock was trading at $28.13, with a drop of $0.19 over the previous days close. The stock recorded -4.12% for the week.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Emergent Biosolutions Inc., Joulwan George A had sold 4,700 shares worth of $207,364 in a transaction dated June 6, 2016. In this transaction, 4,700 shares were sold at $44.12 per share. Currently the company Insiders own 17.2% of Emergent Biosolutions shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -8.89% . Institutional Investors own 84.12% of Emergent Biosolutions shares. During last six month period, the net percent change held by insiders has seen a change of -9.37%.
The company shares have dropped -15.01% from its 1 Year high price. On Jun 7, 2016, the shares registered one year high at $44.38 and the one year low was seen on Jun 28, 2016. The 50-Day Moving Average price is $40.00 and the 200 Day Moving Average price is recorded at $37.58. Emergent Biosolutions (NYSE:EBS): The stock opened at $28.73 on Wednesday but the bulls could not build on the opening and the stock topped out at $28.79 for the day. The stock traded down to $27.92 during the day, due to lack of any buying support eventually closed down at $28.17 with a loss of -0.53% for the day. The stock had closed at $28.32 on the previous day. The total traded volume was 715,886 shares.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Companys two operating divisions include Biodefense and Biosciences. The Companys Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The Biodefense divisions marketed products are BioThrax; BAT; Anthrasil; VIGIV, and RSDL. The Biodefense division investigational stage product candidates include NuThrax, PreviThrax, GC-072 and other biodefense product candidates. The Biosciences divisions marketed products are WinRho SDF, HepaGam B, VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY, ES414 and otlertuzumab.